Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Cipla
Healthtrust
AstraZeneca
McKinsey
Johnson and Johnson
Citi
Chinese Patent Office
US Army

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,182,958

« Back to Dashboard

Which drugs does patent 7,182,958 protect, and when does it expire?

Patent 7,182,958 protects ADCIRCA and CIALIS and is included in two NDAs.

Protection for ADCIRCA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-nine patent family members in twenty-eight countries.
Summary for Patent: 7,182,958
Title:.beta.-carboline pharmaceutical compositions
Abstract:Formulations containing a PDE5 inhibitor, a water-soluble diluent, a lubricant, a hydrophilic binder, a disintegrant, and optional microcrystalline cellulose and/or a wetting agent, and their use in treating sexual dysfunction, are disclosed.
Inventor(s): Oren; Peter L. (Fishers, IN), Anderson; Neil R. (West Lafayette, IN), Kral; Martha A. (Indianapolis, IN)
Assignee: Lilly Icos LLC. (Wilmington, DE)
Application Number:10/031,464
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form; Use;

Drugs Protected by US Patent 7,182,958

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Lilly CIALIS tadalafil TABLET;ORAL 021368-004 Jan 7, 2008 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Lilly CIALIS tadalafil TABLET;ORAL 021368-001 Nov 21, 2003 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Lilly CIALIS tadalafil TABLET;ORAL 021368-002 Nov 21, 2003 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,182,958

PCT Information
PCT FiledApril 26, 2000PCT Application Number:PCT/US00/11130
PCT Publication Date:February 08, 2001PCT Publication Number: WO01/08686

Non-Orange Book US Patents Family Members for Patent 7,182,958

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,841,167 .beta.-carboline pharmaceutical compositions ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,182,958

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 399554 ➤ Try a Free Trial
Australia 4490900 ➤ Try a Free Trial
Australia 4491200 ➤ Try a Free Trial
Australia 776722 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
AstraZeneca
Farmers Insurance
Harvard Business School
Accenture
Fuji
Chubb
Moodys
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.